Anti-(human Growth Differentiation Factor 8) (synthetic Clone Prd-1474 Fibronectin Type Iii Tenth Domain (10fn3)-based Isoform Uses, Dosage, Side Effects and more
Anti-(human Growth Differentiation Factor 8) (synthetic Clone Prd-1474 Fibronectin Type Iii Tenth Domain (10fn3)-based Isoform is under investigation in clinical trial NCT03039686 (Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular Dystrophy).
| Attribute | Details |
|---|---|
| Trade Name | Anti-(human Growth Differentiation Factor 8) (synthetic Clone Prd-1474 Fibronectin Type Iii Tenth Domain (10fn3)-based Isoform |
| Generic | Talditercept alfa |
| Talditercept alfa Other Names | Adnectin, anti-(human growth differentiation factor 8) (synthetic clone prd-1474 fibronectin type iii tenth domain (10fn3)-based isoform, Bms-986089 (fully human anti-myostatin adnectin), Immunoglobulin g1 (human fc fragment) fusion protein with peptide (synthetic 17-amino acid linker) fusion protein with adnectin, anti-(human growth differentiation factor 8) (human clone bms-986089 fibronectin tenth type iii domain-derived), dimer, Taldefgrobep alfa, Talditercept alfa |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
